StocksMedium•12 November 2026•
1 min read
BioStem Technologies Raises 2026 Revenue Guidance Following Hospital Growth
Key Facts
1BioStem Technologies' hospital revenue grew to $6.8 million in the third quarter of 2026.
2The company raised its full-year 2026 revenue guidance based on product portfolio growth.
3Customers purchasing two or more product lines increased by 14% compared to the second quarter.
BioStem Technologies' hospital revenue grew to $6.8 million in the third quarter of 2026. GlobeNewswire reported that the company raised its full-year 2026 revenue guidance based on product portfolio growth, as customers purchasing two or more product lines increased by 14% compared to the second quarter.
BSEM closed at $1.47 on November 11, 2026, with the stock trading between a low of $1.02 and a high of $1.53 during that session. BioStem now expects its full-year 2026 revenue to range between $28 million and $29 million, an upward revision from its previous outlook of $26 million to $29 million.